Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (15182)	1/10/2005 2:24:53 PM
From: quidditch	Respond to of 52153

OSCI: nothing much new: weekly scripts at mid-2000's (c. 2500), but most of Q3 revenues are wholesaler stocking and not scrips Factive most potent chlorquinolone w/ longest patent life (2018); looking for a co-promote partner for Factive to add 400 reps in Q4; have added 150 reps so far since launch, added to the original 100 reps; heavy sampling activity since launch; looking for a second product for the reps to detail signed national Medicaid agreement (to cover 60% of Medicaid patients) effective 1/1/05; Initiating a clinical trial for a five-day Factive treatment of pneumonia; Ramoplanin-very little: P2 complete and are seeking a special protocol assessment with FDA for P3 quid